[HTML][HTML] A genome-wide association study identifies a susceptibility locus to clinically aggressive neuroblastoma at 6p22

JM Maris, YP Mosse, JP Bradfield, C Hou… - The New England …, 2008 - ncbi.nlm.nih.gov
JM Maris, YP Mosse, JP Bradfield, C Hou, S Monni, RH Scott, S Asgharzadeh, EF Attiyeh…
The New England journal of medicine, 2008ncbi.nlm.nih.gov
Background Neuroblastoma is a malignancy of the developing sympathetic nervous system
that most commonly affects young children and is often lethal. The etiology of this embryonal
cancer is not known. Methods We performed a genome-wide association study by first
genotyping 1,032 neuroblastoma patients and 2,043 controls of European descent using the
Illumina HumanHap550 BeadChip. Three independent groups of neuroblastoma cases (N=
720) and controls (N= 2128) were then genotyped to replicate significant associations …
Abstract
Background
Neuroblastoma is a malignancy of the developing sympathetic nervous system that most commonly affects young children and is often lethal. The etiology of this embryonal cancer is not known.
Methods
We performed a genome-wide association study by first genotyping 1,032 neuroblastoma patients and 2,043 controls of European descent using the Illumina HumanHap550 BeadChip. Three independent groups of neuroblastoma cases (N= 720) and controls (N= 2128) were then genotyped to replicate significant associations.
Results
We observed highly significant association between neuroblastoma and the common minor alleles of three single nucleotide polymorphisms (SNPs) within a 94.2 kilobase (Kb) linkage disequilibrium block at chromosome band 6p22 containing the predicted genes FLJ22536 and FLJ44180 (P-value range= 1.71× 10-9-7.01× 10-10; allelic odds ratio range 1.39-1.40). Homozygosity for the at-risk G allele of the most significantly associated SNP, rs6939340, resulted in an increased likelihood of developing neuroblastoma of 1.97 (95% CI 1.58-2.44). Subsequent genotyping of these 6p22 SNPs in the three independent case series confirmed our observation of association (P= 9.33× 10-15 at rs6939340 for joint analysis). Furthermore, neuroblastoma patients homozygous for the risk alleles at 6p22 were more likely to develop metastatic (Stage 4) disease (P= 0.02), show amplification of the MYCN oncogene in the tumor cells (P= 0.006), and to have disease relapse (P= 0.01).
Conclusion
ncbi.nlm.nih.gov